ACC 2019 – Anacetrapib analysis throws doubt on Dalcor play
No genetic correlation was seen with Merck & Co's CETP inhibitor, but Dalcor believes that things will be different for dalcetrapib.
ACC 2019 round-up – Esperion and Amarin prepare to go it alone
As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
ACC 2019 preview – Detection vs diagnosis: Irhythm and the Apple Watch
Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
ACC 2019 preview – Amarin and Esperion look for an edge
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
ACC 2019 preview – Medtronic seeks guidelines change with Tyrx data
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Bayer holds its nerve as patent cliff approaches
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Eidos chases Pfizer in amyloidosis
Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.
Upcoming events – Beacons of hope for Array and Proteon
Array Biopharma hopes for a label extension for its Braf/Mek inhibitor, and Proteon tries to make a better fist of its second phase III trial of vonapanitase.
Regeneron and Sanofi play follow the leader on Praluent pricing
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.